Con­tract re­search is hav­ing a mo­ment right now. Will M&A splash­es dri­ve the in­dus­try to even greater heights?

Con­tract re­search or­ga­ni­za­tions are a fair­ly mys­te­ri­ous bunch. They’re typ­i­cal­ly con­sid­ered the skilled la­bor­ers be­hind big drug de­vel­op­ment — the stage crews who run the tri­als be­hind some of the most (and least) suc­cess­ful da­ta re­veals in bio­phar­ma his­to­ry.

But all that is chang­ing.

This year, a cou­ple of huge, out-of-the-blue M&A deals sound­ed the alarm on just how much mon­ey is fly­ing around in this cor­ner of the in­dus­try.

John Kreger, an an­a­lyst at William Blair, es­ti­mates that about half of all clin­i­cal tri­al work is out­sourced to con­tract re­search or­ga­ni­za­tions, al­so known as CROs. In re­cent years, the com­pa­nies have slow­ly be­gun to take on a new look, with ser­vices now rang­ing from con­sult­ing to man­u­fac­tur­ing and com­mer­cial­iza­tion. It’s an in­dus­try that’s pro­ject­ed to reach $90 bil­lion by 2026, ac­cord­ing to For­tune Busi­ness In­sights. 

“No one has great da­ta about how big this mar­ket is or how much is out­sourced. Every­one’s deal­ing with es­ti­mates,” Kreger said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER